Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | The definitive guide to multiple myeloma at ASH 2018: part V

STORM and TOURMALINE-MM3 impress at ASH 2018
The final chapter of this special tête-à-tête featuring multiple myeloma (MM) leader experts Mohamad Mohty, MD, PhD, from the University Pierre & Marie Curie, Paris, France, and Saad Usmani, MD, FACP, of the University of North Carolina School of Medicine, Chapel Hill, NC, reviews treatment options beyond immunotherapy. Venetoclax, selinexor and axitinib are promising agents in MM and have come under focus during the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Mohty and Dr Usmani share insights on the STORM (NCT02336815) and TOURMALINE-MM3 study (NCT02181413), both presented at ASH 2018.